摘要
目的:了解肺癌患者甘草酸制剂的使用现状,分析其用药特点及趋势。方法:对2014~2017年杭州地区12家医院各种甘草酸制剂的用药金额、用药频度及限定日费用等数据进行统计分析。结果:2014~2017年肺癌患者甘草酸类护肝药物的用药总金额总体呈上升趋势,与2014年相比,2017年用药总金额上升了18.58%,其中用药金额最高的是异甘草酸镁注射液;用药频度居首位的是甘草酸二铵胶囊;序号比大于1的为甘草酸二铵胶囊和复方甘草酸苷片;限定日费用值与用药频度相反,甘草酸二铵胶囊的限定日费用最低,限定日费用最高的为异甘草酸镁注射液。结论:杭州地区12家医院2014~2017年肺癌患者甘草酸类护肝药物的用药金额逐年升高,安全有效、限定日费用较低的甘草酸类药物在临床使用中占优势。
Objective:To study the medication characteristics and tendency of glycyrrhizic liver-protecting drugs through analyzing the utilization in 12 hospitals in Hangzhou area.Methods:The prescriptions data of lung cancer patients in 12 hospitals of Hangzhou from 2014 to 2017 were statistically analyzed,including the consumption,frequency of utilization and defined daily cost.Results:The consumption of lycyrrhizic liver-protecting drugs showed an overall upward trend.Compared with 2014,the total sales amount in 2017 increased by 18.58%,among which the highest sales was magnesium isoglycyrrhizinate injection;The frequency of utilization of diammonium glycyrrhizinate capsules ranked first;The agents with number ratio greater than 1 were diammonium glycyrrhizinate capsules and compand glycyrrhizin tablets.In contrast to frequency of utilization,diammonium glycyrrhizinate capsules had the lowest defined daily cost(DDC),the highest DDC was magnesium isoglycyrrhizinate injection.Conclusion:The consumption of glycyrrhizic liver-protecting drugs for lung cancer patients in 12 hospitals in Hangzhou area from 2014 to 2017 increased year by year.The glycyrrhizic drugs with safe and effective effect and lower DDC were dominant in clinical use.
作者
辛文秀
孙娇
孔思思
陈凌亚
黄萍
Xin Wenxiu;Sun Jiao;Kong Sisi;Chen Lingya;Huang Ping(Department of Pharmacy,Zhejiang Cancer Hospital,Hangzhou 310022,China)
出处
《药物流行病学杂志》
CAS
2019年第8期535-537,552,共4页
Chinese Journal of Pharmacoepidemiology
基金
浙江省中医药科技计划项目(编号:2016ZA035)
浙江省中西医结合学会科研基金项目(编号:2016LYK020)
